Cancer Gene Therapy

Vector Combines IL-4 and HSV-tk for Glioma Tumor Vaccine

Published in Cancer Weekly, June 6th, 2000

Researchers in the United States constructed a retroviral vector that combined interleukin-4 (IL-4) with the herpes simplex virus thymidine kinase (HSV-tk) gene into a glioma tumor cell vaccine.

"Vaccination with cytokine-transduced tumor cells represents a potentially important approach to the treatment of central nervous system tumors," wrote H. Okada and colleagues. "We have recently demonstrated the therapeutic efficacy of tumor cell vaccines expressing the murine IL-4 and the HSV-tk gene in a rat brain tumor model in which nonirradiated vaccine cells can be eliminated by the subsequent administration of ganciclovir.

"In this report, we...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2000-06-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry